Research programme: cancer therapeutics - twoXAR

Drug Profile

Research programme: cancer therapeutics - twoXAR

Alternative Names: TXR-311

Latest Information Update: 22 Mar 2017

Price : $50

At a glance

  • Originator twoXAR
  • Developer Stanford University School of Medicine; twoXAR
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatocellular carcinoma

Most Recent Events

  • 14 Mar 2017 Pharmacodynamics data from a preclinical study in Hepatocellular carcinoma released by twoXAR
  • 13 Mar 2017 Preclinical trials in Hepatocellular carcinoma in USA before March 2017 (unspecified route)
  • 08 Sep 2016 Early research in Hepatocellular carcinoma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top